Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients

Transplantation

Volumn 64, Issue 12, 1997, Pages 1843-1846

  Brennan, Daniel C ^a,b   Garlock, Kathy A ^c   Singer, Gary G ^a   Schnitzler, Mark A ^a   Lippmann, Bruce J ^a   Buller, Richard S ^a   Gaudreault Keener, Monique ^a   Lowell, Jeffrey A ^a   Shenoy, Surendra ^a   Howard, Todd K ^a   Storch, Gregory A ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b 6107 Queeny Tower ^*  (United States)

^c BARNES JEWISH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; GANCICLOVIR;

ADULT; BIOAVAILABILITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; FEMALE; HUMAN; KIDNEY TRANSPLANTATION; MALE; ORAL DRUG ADMINISTRATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VIREMIA;

ADMINISTRATION, ORAL; ADULT; CYTOMEGALOVIRUS INFECTIONS; DIABETES MELLITUS; FEMALE; FOLLOW-UP STUDIES; GANCICLOVIR; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; TIME FACTORS; TISSUE DONORS;

EID: 6844222818     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199712270-00036     Document Type: Conference Paper

References (10)

1. Farrugia E, Schwab TR. Management and prevention of cytomegalovirus infection after renal transplantation. Mayo Clin Proc 1992; 67: 879.
2. Patel R, Snydman DR, Rubin RH, et al. Cytomegalovirus prophylaxis in solid organ transplant recipients. Transplantation 1996; 61: 1279.
3. Brennan DC, Garlock, KA, Lippmann BJ, et al. Control of cytomegalovirus associated morbidity in renal transplant patients using intensive monitoring and either preemptive or deferred therapy. J Am Soc Nephrol 1997; 8: 118.
4. Saliba F, Bismuth H, Gane E, Valdecasas G, O'Grady J, Behrend M, for the Ganciclovir International Transplantation Study Group, Roche Global Development. Efficacy and safety of oral ganciclovir in the prevention of CMV-disease in liver transplant recipients: results of a multicenter, multinational clinical trial [Abstract 248]. International Transplant Society Meeting, Barcelona, Catalonia, August 1996.
5. Solez K, Axelsen RA, Benediktsson H, et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 1993; 44: 411.
6. Schafer P, Tenschert W, Gutnesohn K, Laufs R. Minimal effect of delayed sample processing on results of quantitative PCR for cytomegalovirus DNA in leukocytes compared to results of an antigenemia assay. J Clin Micro 1997; 35: 741.
7. Balfour HH, Chace BA, Stapleton JT, Simmons RL, Fryd DS. A randomized placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med 1989; 320: 1381.
8. Crumpacker CS. Ganciclovir. N Engl J Med 1996;335:721.
9. Bailey TC, Ettinger NA, Storch GA, et al. Failure of high-dose acyclovir with or without immune globulin to prevent primary cytomegalovirus disease in recipients of solid organ transplants. Am J Med 1993; 95: 273.
10. Kletzmayr J, Kotzmann H, Kovarik J, Klauser R, Popow-Kraupp T. Impact of high-dose oral acyclovir prophylaxis on cytomegalovirus (CMV) disease in CMV high-risk renal transplant recipients. J Am Soc Nephrol 1996; 7: 325.